Statistics for Ipilimumab, Nivolumab and Brentuximab Vedotin in Patients with Relapsed Hodgkin Lymphoma: Phase 1 Results of a Multicenter Phase 1/2 Clinical Trial
Total visits
| views | |
|---|---|
| Ipilimumab, Nivolumab and Brentuximab Vedotin in Patients with Relapsed Hodgkin Lymphoma: Phase 1 Results of a Multicenter Phase 1/2 Clinical Trial | 72 |
Total visits per month
| views | |
|---|---|
| October 2024 | 0 |
| November 2024 | 0 |
| December 2024 | 0 |
| January 2025 | 0 |
| February 2025 | 1 |
| March 2025 | 0 |
| April 2025 | 0 |
File Visits
| views | |
|---|---|
| nihms-1625334.pdf | 53 |
| java.util.UUID:e9ed8837-53aa-4102-87bc-66bb3b54e99f | 42 |
| java.util.UUID:6d7d1850-3d8a-4ec1-9392-f818a597ab3e | 14 |
| java.util.UUID:8c244923-f4d9-4dc4-b8fa-f56d0fa10910 | 5 |
Top country views
| views | |
|---|---|
| United States | 63 |
| Canada | 1 |
| Germany | 1 |
| Sweden | 1 |
Top city views
| views | |
|---|---|
| Wilmington | 47 |
| Ashburn | 5 |
| Ann Arbor | 4 |
| Fairfield | 3 |
| Lake Mary | 2 |
| Baltimore | 1 |
| Calgary | 1 |
| Cambridge | 1 |
| Freudenstadt | 1 |
| Kista | 1 |